Anatara Lifesciences (ASX:ANR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Anatara Lifesciences (ASX:ANR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Change of Registry Address Notification
Notice of Annual General Meeting/Proxy Form
Appendix 4G & Corporate Governance Statement
Annual Report to shareholders
Anatara reports lower FY2026 loss as anti-obesity project remains on hold and further capital may be required
Quarterly Activities/Appendix 4C Cash Flow Report
Anatara to manufacture AOC demonstration batch as cash rises to $0.551 million
Date of 2026 Annual General Meeting
Anatara receives $318,402 in R&D Tax Incentive for FY26
Anatara receives $318,402 R&D tax incentive refund
Change of Director's Interest Notice
Application for quotation of securities - ANR
Conversion of Performance Rights and Cleansing Notice
Appendix 4E & Financial Report 30 June 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Anatara Lifesciences reports promising Anti-Obesity pre-clinical results and lodges R&D tax claim